In this episode, Dr. Melissa Thomas (Eli, Lilly & Company), Dr. Elizabeth Niemoller (Sanofi) and Prof. Michele Solimena (Helmholtz Zentrum München & Technical University of Dresden) join host Vivienne Parry to examine how partnerships between academia and industry are transforming diabetes research and care. They discuss the culture shift from cautious collaboration to dynamic, mission-driven partnerships and how initiatives like INNODIA and the Innovative Medicines Initiative (IMI) are delivering real progress for patients. From translational breakthroughs to embedding patient advocates in clinical trial design, they explore why diverse perspectives, early regulatory foresight and shared goals are essential to accelerating therapeutic innovation. 🎧 Listen now for an insider’s look at how public-private partnerships are redefining diabetes science.